Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Dr. Brown on Lessons Learned From RESONATE-2 Trial for CLL
September 6th 2016Jennifer Brown, MD, PhD, director, Chronic Lymphocytic Leukemia Center, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the lessons oncologists have learned from the RESONATE-2 trial, which showed a benefit with ibrutinib (Imbruvica) over chlorambucil in patients with chronic lymphocytic leukemia (CLL).
Dr. Anderson on Future Treatment Landscape of Multiple Myeloma
August 30th 2016Kenneth C. Anderson, MD, a 2014 Giant of Cancer Care in Myeloma, program director, Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics, institute physician, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, discusses how currently available agents will continue to impact the field of multiple myeloma.
Dr. Yurgelun on Educating Patients on Genetic Testing for CRC
August 4th 2016Matthew Yurgelun, MD, instructor in medicine, Harvard Medical School, Dana-Farber Cancer Institute, explains why oncologists should discuss genetic testing with their patients and family members for colorectal cancer, as well as some of the common risk factors for the disease.
APRIL/BCMA Targeted Agent May Block Tumor Growth, Drug Resistance in Myeloma
May 5th 2016Kenneth Anderson, MD, PhD, discusses the role of APRIL/BCMA and what potential the targeted agent BION-1301 may have in blocking multiple myeloma cell proliferation, as well as reducing drug resistance and immunosuppression in the tumor microenvironment.
Dr. Choueiri on FDA Approval of Cabozantinib for RCC
April 26th 2016Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, comments on the FDA approval of cabozantinib as a second-line treatment of patients with renal cell carcinoma (RCC).
Demetri's Team Approach Translates Into Success in Sarcoma Research
George D. Demetri, MD, whose teamwork approach has helped pave the way for new drugs for hard-to-treat sarcomas, was honored in the Gastrointestinal Cancer category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group launched to honor leaders in the field.
Dr. Jennifer Brown on Duvelisib in CLL
November 23rd 2015Jennifer R. Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses duvelisib for the treatment of chronic lymphocytic leukemia (CLL).
How Anderson Transformed Multiple Myeloma Care
Kenneth C. Anderson, MD, has helped transform multiple myeloma from an essentially untreatable disease to a chronic condition. He was honored in the Myeloma category with a 2014 Giants of Cancer Care® award, a program that the Intellisphere® Oncology Specialty Group has launched to honor leaders in the field.
Dr. Toni Choueiri on Cabozantinib and Nivolumab Combination in Kidney Cancer
November 3rd 2015Toni Choueiri, MD, Dana-Farber Cancer, Clinical Director, Lank Center for Genitourinary Oncology, Director, Kidney Cancer Center, Senior Physician, Dana Farber Cancer, discusses the potential for combination treatments in kidney cancer.
Intraperitoneal Chemotherapy Uptake Sluggish in Ovarian Cancer
Frontline treatment with intraperitoneal chemotherapy is commonly underutilized for a majority of patients with optimally cytoreduced stage III ovarian cancer, despite recommendations for its use and a clear demonstration of improved overall survival.
Early Docetaxel, ADT Combo Increases Survival in Advanced Prostate Cancer
August 10th 2015Concomitant therapy with docetaxel and androgen deprivation therapy initiated at the start of treatment for men with metastatic prostate cancer resulted in an increased survival of 13.6 months compared with men who received ADT alone.
Telotristat Etiprate Cuts Carcinoid Syndrome-Related Diarrhea in Phase III Study
Treatment with telotristat etiprate significantly reduced the average number of daily bowel movements compared with placebo for patients with carcinoid syndrome that was not adequately controlled with a somatostatin analog.